To Identify An Enzyme Or Isoenzyme Patents (Class 435/7.4)
  • Publication number: 20150140124
    Abstract: The present invention relates to the BAD pathway's influence on development, progression, chemo-sensitivity, and overall survival for multiple human cancers and its potential as a therapeutic target to increase chemo-sensitivity. BAD pathway expression was associated with the development and/or progression of breast, colon, and endometrial cancers, relapse-free survival from breast cancer, and overall survival from ovarian, colon, and brain cancers. Expression was also associated with in vitro sensitivity to a range of cytotoxic agents. pBAD levels were higher in cancer versus immortalized normal cells and chemo-resistant versus—sensitive cancer cells and associated with increased cell proliferation.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 21, 2015
    Inventors: Johnathan M. Lancaster, Douglas C. Marchion, Yin Xiong
  • Publication number: 20150140127
    Abstract: Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination thereof; b) comparing the level of the TJ protein in the test sample to the level of the TJ protein in a control sample, wherein an elevated level of the TJ protein in the test sample relative to the level of the TJ protein in the control sample indicates that the subject has an injury to the brain.
    Type: Application
    Filed: June 25, 2013
    Publication date: May 21, 2015
    Applicant: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Servio H. Ramirez, Slava Rom, Yuri Persidsky
  • Publication number: 20150139980
    Abstract: Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the assay. Methods for determining ovarian cancer recurrence in an ovarian cancer patient. A method for isolating antibodies specific for ovarian cancer by their affinity to the polypeptide marker antigens, and antibodies isolated by that method.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 21, 2015
    Inventors: Michael Tainsky, Madhumita Chatterjee, Gregory Dyson, Nancy Levin
  • Publication number: 20150141385
    Abstract: Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders, related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 21, 2015
    Inventors: P. Martin Petkovich, Christian F. Helvig, Joel Z. Melnick
  • Publication number: 20150141489
    Abstract: A method of determining a treatment for an inflammatory disorder in a subject, is disclosed. The method comprises determining an amount of SRSF6 in a sample from the subject, wherein an amount of the SRSF6 is indicative of the treatment. Methods of diagnosing inflammatory disorders and treating same are also disclosed.
    Type: Application
    Filed: May 16, 2013
    Publication date: May 21, 2015
    Inventors: Rotem Karni, Vered Ben Hur, Avraham Maimon
  • Patent number: 9034887
    Abstract: A method of identifying an antifungal agent which targets a DHODH protein (alias PyrE, dihydroorotate dehydrogenase, EC: 1.3.99.11) of a fungus comprising contacting a candidate substance with a fungal DHODH protein and determining whether the candidate substance binds or modulates the DHODH protein, wherein binding or modulation indicates that the candidate substance is an antifungal agent. Specific examples concern Aspergillus fumigatus and Candida albicans DHODH proteins. DHODH inhibitors with a Quinazolinone core are also disclosed.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: May 19, 2015
    Assignee: F2G Limited
    Inventors: Jason David Oliver, John Leslie Thain, Michael John Bromley, Graham Edward Morris Sibley, Michael Birch
  • Patent number: 9034321
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: May 19, 2015
    Assignees: aTyr Pharma, Inc., Pangu BioPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Jeffry D. Watkins, Cheryl L. Quinn, Wing-Sze Lo, John D. Mendlein
  • Publication number: 20150133524
    Abstract: The invention provides therapeutic and prophylactic compounds and methods for altering the activity of pyruvate dehydrogenase kinase (e.g. PDK1, PDK2, PDK3, PDK4). Such therapies are useful for the treatment of neoplasia. The invention further provides therapeutic and prophylactic compounds and methods of altering pyruvate dehydrogenase activity to treat or prevent cell death related to ischemia.
    Type: Application
    Filed: October 15, 2014
    Publication date: May 14, 2015
    Inventors: Chi V. Dang, Jung-whan Kim, Gregg L. Semenza
  • Publication number: 20150132772
    Abstract: Methods for diagnosing renal disorders by measuring human neutrophil gelatinase-associated lipocalin (NGAL) are provided.
    Type: Application
    Filed: January 8, 2015
    Publication date: May 14, 2015
    Inventors: Lars Otto Uttenthal, Margarita Ghiglione Juanes, Kristian Bangert
  • Publication number: 20150132769
    Abstract: Compositions and methods for screening for a disease or a disorder associated with a deficiency in frataxin in a subject using biomarkers for diseases or disorders associated with a deficiency in frataxin are disclosed. The compositions and methods include determining the acetylation status of mito-chondrial proteins. Also disclosed are methods of detecting progression of a disease or a disorder associated with a deficiency in frataxin in a subject and methods of monitoring effectiveness of a therapy for diseases or disorders associated with a deficiency in frataxin.
    Type: Application
    Filed: March 1, 2013
    Publication date: May 14, 2015
    Inventors: R. Mark Payne, Gregory R. Wagner, Clifford M. Babbey, P. Melanie Pride
  • Publication number: 20150132771
    Abstract: The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) s PLA2 activity and b) Lipoprotein(a), —combining said measurements, the combined value of s PLA2 activity and Lp(a) being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.
    Type: Application
    Filed: December 17, 2014
    Publication date: May 14, 2015
    Inventors: Ziad Mallat, Sotirios Tsimikas
  • Publication number: 20150133336
    Abstract: The present invention concerns a method of determining whether a non-purified sample contains a target protein bound to a ligand of interest comprising the steps of a) exposing the non-purified sample to a temperature which is capable of causing or enhancing precipitation of the unbound target protein to a greater extent than it is capable of causing or enhancing precipitation of the target protein bound to the ligand; and b) analysing said sample for the presence of soluble or native target protein using two or more affinity reagents capable of binding to said soluble or native target protein with a higher affinity than to an unfolded and/or insoluble form of said target protein. The invention particularly concerns the use of two affinity reagents (e.g. antibodies) which are capable of distinguishing between soluble or native, and unfolded and/or insoluble forms of a target protein and whose detection e.g. by FRET based technology, allows the performance of the method without a separation step.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 14, 2015
    Inventors: Pär NORDLUND, Daniel Martinez MOLINA, Thomas LUNDBÄCK
  • Publication number: 20150132770
    Abstract: The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.
    Type: Application
    Filed: August 22, 2014
    Publication date: May 14, 2015
    Inventors: Claus Oxvig, Michael Toft Overgaard
  • Publication number: 20150126580
    Abstract: Methods for diagnosing and treating cancer associated with an oncogenic Kras mutation in a subject are provided.
    Type: Application
    Filed: December 19, 2012
    Publication date: May 7, 2015
    Inventors: Ronald A. DePinho, Lewis Cantley, Alec C. Kimmelman, Haoqiang Ying, Costas A. Lyssiotis
  • Publication number: 20150126384
    Abstract: The present invention provides methods for assessing an ovarian cancer patient's survival status. Also, methods for evaluating the ovarian cancer state of a patient are described herein. These methods involve the detection, analysis, and classification of biological patterns in biological samples. The biological patterns are obtained using, for example, mass spectrometry systems and other techniques.
    Type: Application
    Filed: November 6, 2013
    Publication date: May 7, 2015
    Applicant: VERMILLION, INC.
    Inventors: Estrid Hogdall, Eric T. Fung, Jarle IB Christensen, Claus Hogdall
  • Publication number: 20150125876
    Abstract: The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27.
    Type: Application
    Filed: December 24, 2014
    Publication date: May 7, 2015
    Applicant: MCBI INC.
    Inventors: Kazuhiko UCHIDA, Kohji MENO, Hideaki SUZUKI
  • Publication number: 20150125452
    Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: Timothy R. Wilson, Hartmut Koeppen, Mark Merchant, Jeffrey Settleman
  • Publication number: 20150126622
    Abstract: Necrotizing Enterocolitis (NEC) biomarkers, NEC biomarker panels, and methods for obtaining a NEC signature for a sample are provided. Also provided are methods, compositions, and kits for making a Necrotizing Enterocolitis (NEC) assessment of an individual, e.g. for diagnosing NEC in a patient, prognosing NEC in a patient, treating an NEC patient, etc. These methods find use in a number of applications, such as diagnosing and treating infants who are suspected of having NEC, intestinal perforation (IP), or sepsis.
    Type: Application
    Filed: June 10, 2013
    Publication date: May 7, 2015
    Inventors: Karl G. Sylvester, Guozhong Tao
  • Publication number: 20150125466
    Abstract: The present invention relates to method for predicting a subject's relative response to cancer immunotherapy treatment. The methods involve providing a sample comprising a tumor cell or a peripheral blood cell from the subject; measuring the expression level of matrix metalloproteinase-23 (“MMP-23”) by the tumor cell or the peripheral blood cell; comprising the measured expression level of MMP-23 with a control or standard value; and determining the subject's predicted response to cancer immunotherapy, where, based on said comparing, a higher MMP-23 expression level compared to the control or standard value predicts the subject will have a poor response to cancer immunotherapy. The present invention also relates to methods for increasing production of tumor infiltrating leucocytes (“TILs”) in a subject, methods of identifying a subject as a candidate for adoptive T-cell therapy using T-cells that primarily express KCa3.
    Type: Application
    Filed: May 1, 2013
    Publication date: May 7, 2015
    Inventors: Michelle Krogsgaard, Iman Osman
  • Publication number: 20150118699
    Abstract: Markers useful in diagnosing disseminated intravascular coagulation (DIC) or infectious DIC are provided. In a method for detecting DIC of the present invention, sCD14-ST in a sample is measured. In a method of detecting infectious DIC of the present invention, sCD14-ST and a coagulation-related marker in a sample are measured.
    Type: Application
    Filed: April 26, 2013
    Publication date: April 30, 2015
    Inventor: Hiroyasu Ishikura
  • Publication number: 20150118248
    Abstract: The application describes a method of screening for breast cancer by testing fro the amount of HAGE (Helicase antigen) in a sample of breast tissue. Methods of prognosis of samples of breast cancer tumours are also provided. HAGE+ ER? (estrogen receptor-) cancers are indicated as being amenable to chemotherapy. Methods of treating breast cancers with HAGE-specific CTA antigen or HAGE-specific antibodies are also provided.
    Type: Application
    Filed: March 27, 2013
    Publication date: April 30, 2015
    Inventors: Adam Linley, Morgan Mathieu, Stephanie Mcardle, Chungui Lu, Robert Rees
  • Publication number: 20150119281
    Abstract: A phosphine derivative of DyLight dyes modified with ethylene glycol or (poly)ethylene glycol groups. In one embodiment, the compounds are useful in chemoselective ligation reactions.
    Type: Application
    Filed: October 29, 2014
    Publication date: April 30, 2015
    Applicants: Pierce Biotechnology, Inc., Dyomics GmbH
    Inventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Suk J. Hong, Matthias S. Wenzel, Boguslawa R. Dworecki, Frank G. Lehmann
  • Publication number: 20150119282
    Abstract: Markers are provided for genetic and epigenetic diagnosis of embryos to determine those of which are more likely to be chromosomally normal and advance in development.
    Type: Application
    Filed: October 30, 2014
    Publication date: April 30, 2015
    Inventors: Shawn L. Chavez, Renee A. Reijo Pera, Sohyun L. McElroy, Barry Behr, Lynn M. Westphal
  • Publication number: 20150119475
    Abstract: The use of Akt3 as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of Akt3 inhibitors to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Akt3 expression and/or activity.
    Type: Application
    Filed: May 2, 2013
    Publication date: April 30, 2015
    Inventors: Jim Lorens, Crina Tiron
  • Publication number: 20150119263
    Abstract: Disclosed are devices that comprise a protein, such as an antibody, placed into electronic communication with a semiconductor material, such as a carbon nanotube. The devices are useful in assessing the presence or concentration of analytes contacted to the devices, including the presence of markers for prostate cancer and Lyme disease.
    Type: Application
    Filed: August 30, 2012
    Publication date: April 30, 2015
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, FOX CHASE CANCER CENTER
    Inventors: Alan T. Johnson, JR., Mitchell Lerner, Matthew K. Robinson, Tatiana Pazina, Dustin Brisson, Jennifer Dailey
  • Publication number: 20150118675
    Abstract: The present invention provides an immunochromatography detection method capable of suppressing non-specific reactions. The present invention relates to an immunochromatography detection method including: a step of adding an analyte dilution solution containing an analyte to a chromatography medium; a step of recognizing a detection target by a labeling substance modified with gold nanoparticles, which is dry-retained at a labeling substance retaining part; a step of developing a composite of the labeling substance and the detection target as a mobile phase; and a step of detecting the detection target in the developed mobile phase at a judgment part, wherein the labeling substance is protected with a polyalkylene glycol having one or more mercapto groups and/or a derivative thereof and then dry-retained together with arginine and casein at the labeling substance retaining part.
    Type: Application
    Filed: March 13, 2013
    Publication date: April 30, 2015
    Inventor: Daisuke Ito
  • Publication number: 20150118686
    Abstract: The present invention provides a method for screening and evaluating ameliorants of dry skin caused by atopic dermatitis, comprising: evaluating a candidate drug as being an ameliorant of dry skin caused by atopic dermatitis in the case the candidate drug significantly increases expression and/or activity of bleomycin hydrolase in comparison with a control drug.
    Type: Application
    Filed: November 6, 2014
    Publication date: April 30, 2015
    Applicant: Shiseido Company, Ltd.
    Inventors: TOSHIHIKO HIBINO, YAYOI KAMATA, MAMI YAMAMOTO
  • Publication number: 20150118155
    Abstract: The present invention provides a method of diagnosing the existence or risk of hyperthyroidism in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of e.g., IYD, TG, SLC5A5, NIS, TPO, TSHR, DUOX1, DUOX2 (ThOX), TGFB1, CSTD, DCN and SEPP1 and the expression products thereof, in a biological sample from the feline, wherein elevated expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal feline or feline population, or a baseline value from the feline, indicates the existence or risk of hyperthyroidism; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods.
    Type: Application
    Filed: June 14, 2012
    Publication date: April 30, 2015
    Applicant: Hill's Pet Nutrition, Inc.
    Inventors: Samer Al-Murrani, Xiangming Gao
  • Publication number: 20150119410
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Application
    Filed: October 26, 2012
    Publication date: April 30, 2015
    Applicants: Millennium Pharmaceuticals, Inc, Massachusetts General Hospital
    Inventors: Cyril H. Benes, Stephen J. Blakemore, Jonathan L. Blank, Eric S. Llightcap, George J. Mulligan, Matthew C. Schu, Peter G. Smith, Jeffrey E. Settleman
  • Publication number: 20150118690
    Abstract: A sample analyzer has an illuminator for illuminating an assay sample to cause luminescence, and a support for a sample vessel containing the assay sample. The support is adapted to position the assay sample proximate the illuminator. A detector is positioned along an optical axis extending from the illuminator, through the positioned assay sample, to the detector, so as to detect the luminescence from the assay sample. A reflector is removably disposed between the illuminator and the assay sample so as to reflect a portion of the luminescence back through the positioned assay sample toward the detector.
    Type: Application
    Filed: April 23, 2013
    Publication date: April 30, 2015
    Applicant: Siemens Healthcare Diagnostic Inc.
    Inventors: Jeffrey R. Jasperse, Normand P. Desmarais
  • Publication number: 20150118691
    Abstract: A method for the simultaneous measurement of proteolylic enzyme generation and clot strength in plasma or whole blood or any appropriate biological sample derived from blood. The measurement method encompasses the use of a detectable substrate which includes a moiety that can be released upon reaction with the targeted proteolytic enzyme, and elements for measurement of an increase in viscosity of clot strength.
    Type: Application
    Filed: June 20, 2013
    Publication date: April 30, 2015
    Inventors: Bas H. De Laat, Hendrik Coenraad Hemker, Leonie Pelkmans, Hilde Kelchtermans
  • Publication number: 20150119254
    Abstract: An object of the present invention is to develop and provide a method for efficiently producing a nucleic acid aptamer, particularly, a DNA aptamer, having higher specificity and binding activity against a target substance than those of nucleic acid aptamers obtained by conventional methods. The present invention provides a transcribable or replicable nucleic acid aptamer comprising a natural nucleotide and a non-natural nucleotide having an artificial base-pairable artificial base. The present invention also provides a method for sequencing a non-natural nucleotide-containing single-stranded nucleic acid molecule selected from a single-stranded nucleic acid library.
    Type: Application
    Filed: November 15, 2012
    Publication date: April 30, 2015
    Inventors: Ichiro Hirao, Michiko Hirao, Rie Yamashige, Shigeyuki Yokoyama
  • Publication number: 20150118221
    Abstract: The present invention relates to the field of cardiology. More specifically, the present invention provides methods and compositions useful for treating cardiac hypertrophy. In a specific embodiment, a method for treating or preventing cardiac hypertrophy in a patient comprises the step of administering a therapeutically effective amount of a glycolipid synthesis inhibitor.
    Type: Application
    Filed: May 8, 2013
    Publication date: April 30, 2015
    Applicant: The John Hopkins University
    Inventor: Subroto Chatterjee
  • Patent number: 9017957
    Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: April 28, 2015
    Assignees: Hitachi Chemical Company, Ltd., Kimio Tomita, Kenichiro Kitamura
    Inventors: Hiromi Iijima, Noriya Ohta, Kimio Tomita, Kenichiro Kitamura
  • Publication number: 20150110833
    Abstract: Macromolecular imprinted silica particles (“MIP”) in the presence of polymer grafted carbon black are disclosed. The disclosed molecular imprinted beads can detect disease in body fluids. For the silica gel matrix, tetraethyl orthosilicate (TEOS) was used as the backbone monomer and 3-aminopropy/triethoxysilane (APS) as a functional monomer. Carbon black was added to the sol-gel process, yielding black silica particles. Furthermore, sodium dodecyl sulfate (SDS) was used as a structure-directing agent to increase network diffusion of the template. A total of 16 MIPs were synthetized in parallel with variables that evaluate the role of key reactants in the synthesis procedure. Agglomeration tests were performed with all 16 MIPs in the presence of their template, alongside their respective controls using only phosphate buffered saline (“PBS”). Each of the MIPs was evaluated using a novel device capable of simultaneously measuring up to four samples for near infrared transmission.
    Type: Application
    Filed: August 6, 2014
    Publication date: April 23, 2015
    Inventor: Thomas Boland
  • Publication number: 20150111758
    Abstract: The present invention relates to compositions, kits, and methods for providing a prognosis and/or determining a treatment course of action in a subject diagnosed with breast cancer. In particular, the present invention relates to gene expression signatures useful in the prognosis, diagnosis, and treatment of breast cancer.
    Type: Application
    Filed: March 6, 2013
    Publication date: April 23, 2015
    Inventors: Therese Sorlie, Arnoldo Frigessi, Anne-Lise Borresen-Dale, Simen Myhre, Hayat Mohammed, Jens Overgaard, Jan Alsner, Trine Tramm
  • Publication number: 20150111927
    Abstract: The present invention relates to selective cancer treatment regimes based on assaying for the presence or absence of a glutamine or a nucleic acid that encodes glutamine at position 859 of the catalytic p110? subunit of PI3K; methods for producing a transmittable form of information for predicting the responsiveness of patient to (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or a pharmaceutically acceptable salt thereof; and a kit thereof.
    Type: Application
    Filed: March 27, 2013
    Publication date: April 23, 2015
    Inventors: Pascal Furet, Christine Fritsch, Sauveur-Michel Maira
  • Publication number: 20150111223
    Abstract: The disclosed methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management. The methodology provided herein is intended to detect technical variations and to allow for data normalization and enhance signal detection and build predictive proteins profiles of disease status and response.
    Type: Application
    Filed: October 28, 2014
    Publication date: April 23, 2015
    Inventors: John Blume, Ryan Benz, Lisa Croner, Roslyn Dillon, Arlo Z. Randall, Jeffrey Jones, Heather Skor, Tom Stockfisch, Bruce Wilcox, Daniel Ruderman
  • Publication number: 20150110718
    Abstract: The present invention is directed to methods and assays for identifying subjects participating in clinical trials that may exhibit a placebo response and identifying treatments for subjects with varying degrees of placebo responses. In one aspect, a method of selecting subjects to participate in a clinical trial is disclosed. In another aspect, methods for treating a subject and determining a treatment dosage are disclosed. In an exemplary embodiment, a method for determining a response to a treatment of a subject having, suspected of having, or at risk for developing a disorder, such as cardiovascular disorder, irritable bowel syndrome, diabetes, autoimmune disorders, inflammation, neurological disorders, chronic pain, cancer, cancer treatments, allergies, depression, migraines, addiction, obesity, and other disorders, syndromes, or diseases, is disclosed.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 23, 2015
    Inventors: Gunther Winkler, Kathryn T. Hall, Ted J. Kaptchuk
  • Publication number: 20150111776
    Abstract: The present disclosure provides immunoassays using one or more over-labeled fluorescent probes, which provides for rapid, accurate and quantitative detection of one or more target analytes in sample, reading fluorescent intensity. The disclosed immunoassays provide multiplexing capability with low cross-reactivity.
    Type: Application
    Filed: September 23, 2014
    Publication date: April 23, 2015
    Inventor: Henry J.X. Chen
  • Publication number: 20150110773
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Application
    Filed: May 23, 2013
    Publication date: April 23, 2015
    Inventors: Alec C. Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • Patent number: 9012159
    Abstract: A method for identifying a compound which modulates the activity of acyl-coA: diacylglycerol acyltransferase comprises the steps of contacting a stable isotope labeled fatty acid with cells in either presence or absence of the compound, extracting the cells with isopropyl alcohol, and determining the level of a stable isotope labeled triglyceride in the presence or absence of the compound; wherein a change in the level of the stable isotope labeled triglyceride indicates that the compound modulates the DGAT activity.
    Type: Grant
    Filed: January 7, 2010
    Date of Patent: April 21, 2015
    Assignee: Janssen Research & Development, LLC
    Inventors: Jian-Shen Qi, Wensheng Lang, Margery A. Connelly
  • Publication number: 20150105291
    Abstract: It is intended to evaluate an ischemic heart disease with high accuracy by convenient operation. The method for evaluating an ischemic heart disease according to the present invention comprises the steps of: assaying complement factor H and/or complement factor D in a sample derived from the blood of a test subject; and comparing the concentration of the complement factor H and/or the concentration of the complement factor D assayed in the preceding step with a reference value(s), wherein it is determined that the seriousness of the ischemic heart disease is high when the concentration falls below the reference value.
    Type: Application
    Filed: October 15, 2014
    Publication date: April 16, 2015
    Inventors: Hiroko HANZAWA, Takeshi SAKAMOTO, Yuji KUGE
  • Publication number: 20150104806
    Abstract: The present invention relates to a biomarker for Parkinson's disease. The biomarker and products associated with the biomarker may be used to assist diagnosis or to assess onset and/or development of Parkinson's disease. The invention also relates to use of the biomarker in clinical screening, assessment of prognosis, evaluation of drug treatments, drug screening or drug development in the field of Parkinson's disease and Parkinson's disease related disorders.
    Type: Application
    Filed: April 10, 2013
    Publication date: April 16, 2015
    Applicant: University of Dundee
    Inventors: Dario Alessi, Muratul Muqit
  • Publication number: 20150104807
    Abstract: The present invention provides for methods and kits for detecting sepsis, trauma/hemorrhage or inflammation in a subject. It is based, at least in part, on the discovery that Augmenter of Liver Regeneration (“ALR”) is an early marker of these conditions. Accordingly, in other embodiments, the present invention provides for a method of treating sepsis, traumatic/hemorrhagic shock and inflammation by inhibiting ALR.
    Type: Application
    Filed: August 19, 2014
    Publication date: April 16, 2015
    Applicant: University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: CHANRASHEKHAR R. GANDHI, Yoram Vodovotz
  • Patent number: 9005909
    Abstract: A method of sample analysis is provided. In certain embodiments, the method comprises: a) labeling cells of a blood sample using an antibody that specifically binds to phospho-AMPK or a phosphorylated target thereof, to produce a labeled sample; and b) measuring antibody binding by a population of blood cells of the labeled sample using flow cytometry. In particular embodiments, the method may further comprise, prior to the labeling step: contacting blood with a test agent ex vivo or in vivo; and comparing the evaluation to results obtained from a reference sample of blood cells.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: April 14, 2015
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vadim Markovtsov, Yasumichi Hitoshi
  • Publication number: 20150099802
    Abstract: A method for treating a tumor with a decreased level of the 15-hydroxy-prostaglandin dehydrogenase (15-PGDH) in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative, a method for suppressing the growth of a tumor cell with a decreased level of the 15-hydroxy-prostaglandin dehydrogenase (15-PGDH), which comprises contacting said tumor cell with an effective amount of a fatty acid derivative, and a method for identifying a subject who would be responsive to a fatty acid derivative, comprising, (i) obtaining a biological sample from said subject; and (ii) measuring 15-hydroxyprostaglandin dehydrogenase (15-PGDH) level are provided.
    Type: Application
    Filed: October 1, 2014
    Publication date: April 9, 2015
    Applicant: SUCAMPO AG
    Inventors: Ryuji UENO, Sachiko KUNO
  • Publication number: 20150099645
    Abstract: The present invention discloses a method of detecting T-cell proliferation in a subject comprising the steps of (a) obtaining a sample from said subject; and (b) profiling at least one parameter selected from the group consisting of: the activation level of GSK-3?, the expression level of GSK-3? and the activation or expression level of related members of pathways in which GSK-3? plays a part. It is a core aspect of the invention, wherein a significant deviation from normal values indicates cellular proliferation. The present invention further discloses kits for detecting T-cell proliferation.
    Type: Application
    Filed: March 14, 2013
    Publication date: April 9, 2015
    Inventor: Stephen MARX
  • Publication number: 20150099270
    Abstract: A method of determining nephrotoxicity of pharmaceuticals by conducting a metabolite formation study in cells using PAH in a control group; measuring metabolite formation; exposing cells to pharmaceuticals in the treatment group; conducting the metabolite formation study using PAH; measuring the metabolite formation in the treatment group; comparing the metabolite formation in the control and treatment group, and making a determination as to the nephrotoxicity of pharmaceutical.
    Type: Application
    Filed: October 6, 2014
    Publication date: April 9, 2015
    Inventor: Thomas C. DOWLING
  • Patent number: 8999658
    Abstract: The presently-disclosed subject matter provides methods and kits for diagnosing obstructive sleep apnea (OSA) in a subject, such as a human child, wherein a biological sample is provided from the subject and the amount of a Urocortin III peptide is determined from the sample. Further provided are methods for diagnosing OSA in a subject wherein the amount of a Urocortin III peptide and one or more peptides selected from a Uromodulin peptide, an Orosomucoid 1 peptide, and a Kallikrein 1 peptide are determined in a biological sample from a subject.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: April 7, 2015
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: David Gozal, Saeed A. Jortani, Roland Valdes, Jr., Leila Kheirandish-Gozal